Aristotle study is a phase III study which evaluates apixaban’s safety and efficacy as comparing to warfarin in patients with nonvalvular AF (NVAF) having at least one stroke risk factor of apixaban. 18.201 patients were evaluated in this randomized, controlled, multicentered study. This review will overview of the Aristotle study and subgroup analysis.
Keywords: Aristotle, apixaban, nonvalvular.